- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
Bexitrol F
Dry Powder Inhalation Capsule (DPI)
Generic Name
Salmeterol + Fluticasone Propionate
Manufacturer
Beximco Pharmaceuticals Ltd.
Unit Price
Unit Price: ৳ 6.50 (3 x 10: ৳ 195.00) Strip Price: ৳ 65.00
🔹 Indications
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
🔹 Pharmacology
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Dosage & Administration
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Interaction
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Contraindications
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Side Effects
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Pregnancy & Lactation
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Precautions & Warnings
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Pediatric Usage
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
🔹 Storage Conditions
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
- Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
💡 Frequently Asked Questions
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled...
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled...
Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled...
User Reviews
⭐
No reviews yet!
Be the first to share your experience.